Floatz logo

XP-102

Thyroid Cancer

Xynomic Pharmaceuticals, Inc.Small moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

41 Active assets in the Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kineta Inc.
Phase 2BB
ALECTINIB
Hoffmann-La Roche
Phase 2B
Denosumab
Amgen
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
[68ga]ga-nota-rt4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

XP-102 is also rated in:

BRAF V600 MutationDormant
CC
Indicative ·
47 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →